Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA; ROCKET AF Investigators. Singer DE, et al. Among authors: califf rm. J Am Heart Assoc. 2013 Feb 19;2(1):e000067. doi: 10.1161/JAHA.112.000067. J Am Heart Assoc. 2013. PMID: 23525418 Free PMC article. Clinical Trial.
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, Topol EJ, Califf RM. Zabel KM, et al. Among authors: califf rm. Am Heart J. 1998 Nov;136(5):868-76. doi: 10.1016/s0002-8703(98)70133-4. Am Heart J. 1998. PMID: 9812083 Clinical Trial.
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.
Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: califf rm. Am Heart J. 1999 Sep;138(3 Pt 1):493-9. doi: 10.1016/s0002-8703(99)70152-3. Am Heart J. 1999. PMID: 10467200 Clinical Trial.
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: califf rm. Eur Heart J. 2000 Mar;21(5):371-81. doi: 10.1053/euhj.1999.1743. Eur Heart J. 2000. PMID: 10666351 Clinical Trial.
Redefining medical treatment in the management of unstable angina.
Braunwald E, Califf RM, Cannon CP, Fox KA, Fuster V, Gibler WB, Harrington RA, King SB 3rd, Kleiman NS, Theroux P, Topol EJ, Van de Werf F, White HD, Willerson JT. Braunwald E, et al. Among authors: califf rm. Am J Med. 2000 Jan;108(1):41-53. doi: 10.1016/s0002-9343(99)00416-7. Am J Med. 2000. PMID: 11059440 Review.
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
O'Connor CM, Gattis WA, Hellkamp AS, Langer A, Larsen RL, Harrington RA, Berkowitz SD, O'Gara PT, Kopecky SL, Gheorghiade M, Daly R, Califf RM, Fuster V. O'Connor CM, et al. Among authors: califf rm. Am J Cardiol. 2001 Sep 1;88(5):541-6. doi: 10.1016/s0002-9149(01)01735-0. Am J Cardiol. 2001. PMID: 11524065 Clinical Trial.
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Mahaffey KW, et al. Among authors: califf rm. Am Heart J. 2002 Feb;143(2):242-8. doi: 10.1067/mhj.2002.120145. Am Heart J. 2002. PMID: 11835026
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ. Mukherjee D, et al. Among authors: califf rm. Am Heart J. 2002 Dec;144(6):995-1002. doi: 10.1067/mhj.2002.126118. Am Heart J. 2002. PMID: 12486423 Clinical Trial.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, Gore J, Weaver WD, Longstreth WT Jr, Stebbins A, Lee KL, Califf RM, Topol EJ; Global Utilization of Streptokinase and tPA for Occluded Arteries-I Investigators. Kandzari DE, et al. Among authors: califf rm. Am J Cardiol. 2004 Feb 15;93(4):458-61. doi: 10.1016/j.amjcard.2003.10.043. Am J Cardiol. 2004. PMID: 14969623
1,320 results